UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 9, 2010 (December 8, 2010)
Alnylam Pharmaceuticals, Inc.
(Exact Name of Registrant as Specified in Charter)
| |
|
|
|
|
|
| Delaware
|
|
000-50743
|
|
77-0602661 |
| |
(State or Other Juris-
diction of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.) |
| |
|
|
|
| 300 Third Street, Cambridge, MA
|
|
02142 |
| |
| (Address of Principal Executive Offices)
|
|
(Zip Code) |
Registrant’s telephone number, including area code: (617) 551-8200
Not applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy
the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment
of Principal Officers; Compensatory Arrangements of Certain Officers.
(d) On December 8, 2010, the Board of Directors (the “Board”) of Alnylam Pharmaceuticals, Inc.
(the “Company”) elected Marsha H. Fanucci as a Class II director with a term expiring at the annual
meeting of stockholders to be held in 2012. In connection with her election to the Board, Ms.
Fanucci received a stock option grant for 30,000 shares of common stock of the Company, vesting
annually over three years, and will be compensated as a director pursuant to the Company’s
compensation policy for non-employee directors, which is described in the Company’s Proxy Statement
for the 2010 Annual Meeting of Stockholders filed with the Securities and Exchange Commission on
April 20, 2010.